CGRP Forum is made possible thanks to support from AbbVie, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »

New US migraine guidelines recommend anti-CGRP therapies for migraine prevention Reassuring persistence rates with CGRP mAb therapy in adolescents and adults ECLIPSE analyses show consistent atogepant effects across multiple migraine attacks Premonitory symptoms during CGRP mAb therapy Who can ‘graduate’ from CGRP mAbs?Long term triple therapy in chronic migraine PACAP-38 is detectable in tears Eptinezumab improves migraine-related cognitive symptoms

Educational Partners and Supporters

CGRP Education and Research Forum is made possible thanks to support from industry leaders, all of whom have no influence or control over editorial content.

	This program is funded in part via an independent educational grant from AbbVie.

	Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
	Supported by an independent grant from Pfizer.

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Supported by an independent grant from Pfizer.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2026 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |